XB130在上皮性卵巢癌中的表达及与预后的关系

Expression of XB130 in Epithelial Ovarian Cancer and Its Associated with Prognosis

[目的]研究XB130在上皮性卵巢癌中的表达水平及与预后的关系。[方法]通过免疫组织化学技术（IHC）检测141例卵巢恶性组织及100例良性组织中XB130的蛋白质表达强度及表达位置;通过Western blot技术检测术后新鲜卵巢恶性组织40例及良性组织40例中XB130的蛋白质表达程度。采用χ2或者t检验来检测XB130表达情况与临床病理特征之间的关系。采用Kaplan-Meier法计算生存曲线。[结果]免疫组化方法显示XB130主要位于细胞质中,在卵巢恶性组织中的阳性率达78%,明显高于良性组织的39%（P=0.000）。Western blot结果显示XB130在卵巢恶性组织中相对表达量为2.8200±1.1747,明显高于良性组织2.1075±1.0884（P=0.027）。XB130表达程度与FIGO分期、分化程度、淋巴结转移存在显著性相关（P均〈0.05）,而与年龄、腹膜种植无明显关系（P〉0.05）。XB130阳性患者的总生存期低于XB130阴性患者（P〈0.05）。[结论]XB130表达水平与卵巢组织良恶性有关,XB130阳性患者的预后较差,生存期较短,XB130可能参与了卵巢癌的发展。

[Objective] To investigate the relationship between expression of XB130 in epithelial ovarian cancer and its associated with prognosis. [Methods] The expressions of XB130 in 141 cases of malignant ovarian tissues and 100 cases of benign tissues were detected with immunohistochemical technique（IHC）,and the expression XB130 level in fresh tissue of 40 cases of ovarian malignant and benign tissue in 40 cases was detected by Western blotting after surgery. Chi square test or t test was used to examine the relationship between the expression of XB130 and clinicopathological features. The survival curve was calculated by Kaplan-Meier method. [Results] The positive of XB130 was located in cytoplasm mainly,positive rate of XB130 in ovarian malignant tissues was 78% with the IHC,higher than that in benign tissues with the value of 39%（P =0.000）. The method of Western blotting confirmed that the relative expression of XB130 in ovarian malignant tissue was 2.8200 ±1.1747,which was significantly higher than that in benign tissue by2.1075±1.0884（P=0.027）. The expression of XB130 was significantly related to FIGO staging,differentiation and lymph node metastasis（P all 0.05）,but showed no significant relationship with age and peritoneal implant（P〈0.05）. The overall survival of XB130 positive patients was lower than that in XB130 negative patients（P〈0.05）. [Conclusion] There is a relationship between the expression of XB130 and the benign or malignant ovarian tissues.And there is a poor prognosis of XB130 positive patients,short survival. XB130 may be involved in the development of ovarian cancer.